Agilent Technologies, Inc. (A) स्टॉक विश्लेषण

कंपनी का अवलोकन

Agilent Technologies, Inc. delivers application-focused solutions to the global life sciences, diagnostics, and applied chemical markets through its specialized operations. The enterprise functions within the Healthcare sector, specifically targeting the Diagnostics & Research industry, which implies a reliance on scientific instrumentation and laboratory equipment for critical medical and research applications. This entity commands a significant market capitalization of $32.64B and generates annual revenue of $7.06B while employing a workforce of 18,000 individuals. These financial dimensions suggest that the company holds a substantial position in its industry, supported by a robust revenue base that facilitates extensive global operations and R&D investments.

वित्तीय स्वास्थ्य

The company reported a Trailing Twelve Months revenue of $7.06B with a Net Income of $1.29B and an EBITDA of $1.97B, highlighting a structural cost composition where operating expenses consume approximately 81.7% of total revenue before interest and taxes. The Free Cash Flow stands at $855.88M, indicating strong cash generation capabilities that provide substantial financial flexibility for capital allocation, debt servicing, or potential share buybacks without requiring external financing. Profitability analysis reveals a Gross Margin of 52.3%, an Operating Margin of 22.9%, and a Profit Margin of 18.3%, demonstrating that the company retains a significant portion of sales revenue after accounting for the cost of goods sold, operating overhead, and total expenses. Liquidity assessment shows the company holds $1.76B in cash against $3.55B in debt, resulting in a Debt to Equity ratio of 51.39% which suggests a balanced leverage profile rather than an overly aggressive or overly conservative balance sheet structure. Short-term liquidity is well-secured as evidenced by a Current Ratio of 2.07, meaning the company possesses more than double the current assets necessary to cover its immediate liabilities. Efficiency metrics are reflected in a Return on Equity of 19.9% and a Return on Assets of 8.5%, indicating that management effectively utilizes shareholder capital and total assets to generate profits relative to the industry standards for capital-intensive technology firms.

मूल्यांकन आकलन

The valuation metrics present a Trailing P/E Ratio of 25.47 compared to a Forward P/E of 17.53, suggesting that the market expects earnings growth in the future that would lower the multiple, although current earnings are priced at a premium relative to forward expectations. The Price to Book ratio stands at 4.72, indicating that the market values the company at a significant premium over its net asset book value, reflecting the high intangible value of its intellectual property and brand strength. Alternative valuation measures include a Price to Sales ratio of 4.62 and an EV/EBITDA of 17.45, which provide context on how revenue and operating cash flows are valued relative to the enterprise value, often used to compare capital-intensive diagnostic firms. Historical price volatility is captured by a 52-week high of $160.27 and a 52-week low of $96.43, where the current trading price sits within this established range but remains below the annual peak, reflecting recent market adjustments. The Beta value is recorded at 1.30, signifying that the stock exhibits higher price volatility relative to the broader market index, moving approximately 30% more than the overall market during periods of equity market fluctuation.

Growth & Income

Recent performance data indicates a Revenue Growth of 7.0% Year-over-Year contrasted with an Earnings Growth of -3.6% Year-over-Year, revealing that while top-line sales are expanding, profit margins are currently under pressure causing earnings to lag behind revenue expansion. Regarding income distribution, the company maintains a Dividend Yield of 0.9% with a Payout Ratio of 22.0%, a conservative payout level that appears highly sustainable given the strong Free Cash Flow generation and low payout percentage relative to earnings. The current earnings contraction does not threaten dividend sustainability as the low payout ratio leaves ample room for retention of earnings during periods of earnings volatility. Overall, the growth and income profile reflects a mature company prioritizing steady revenue expansion and capital retention over aggressive earnings growth or high dividend yields, typical of established healthcare technology leaders.